Travere Therapeutics, Inc.
TVTX
Κατάταξη σε μετοχές
#3418
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Τιμή μετοχής
$52.95
Τελευταίος συγχρονισμός: 2026-10-21
Κεφαλαιοποίηση
$4.99B
Αλλαγή (1 ημέρα)
1.24%
Αλλαγή (1 έτος)
92.69%
Χώρα
US
Εμπόριο Travere Therapeutics, Inc. (TVTX)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Travere Therapeutics, Inc. (TVTX)
Υψηλότερη τιμή κλεισίματος: $53.35 στις 2026-10-01
Χαμηλότερη τιμή κλεισίματος: $1.88 στις 2012-11-01
Χαμηλότερη τιμή κλεισίματος: $1.88 στις 2012-11-01
Ιστορικό τιμής μετοχής της Travere Therapeutics, Inc. από 2012 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | 21.63% |
| 2025 | 98.56% |
| 2024 | 113.02% |
| 2023 | -57.16% |
| 2022 | -32.13% |
| 2021 | 10.99% |
| 2020 | 87.35% |
| 2019 | -40.02% |
| 2018 | 7.59% |
| 2017 | 9.33% |
| 2016 | -3.75% |
| 2015 | 81.19% |
| 2014 | 54.72% |
| 2013 | 74.64% |
| 2012 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
